Jinge Zhili Powder Veterinary Grade API enters direct-compression tablet production only after laser diffraction confirms a D₉₀ of ≤ 250 μm and a D₅₀ of 90–180 μm; material retained on a 710 μm sieve is held below 5.0 wt% because oversized fractions segregate in rotary press force feeders above 60 rpm and generate content uniformity failures. Low-dose companion-animal tablets are formulated at 2.0–10.0 wt% API with a 1:1 to 1:5 ratio of API to a direct-compression diluent system of microcrystalline cellulose, anhydrous lactitol and croscarmellose sodium; high-dose veterinary boluses are processed at 15.0–35.0 wt% API. Blending is executed in a 500 L bin blender at 12–15 rpm for 20–30 min with triplicate sampling at top, middle and bottom positions; a blend relative standard deviation of ≤ 5.0% is required before tablet press release. Compression is performed on a rotary tablet press with precompression force 8–12 kN and main compression force 20–30 kN; tablet fracture resistance is targeted at 5–10 kp according to Ph. Eur. 2.9.1, and disintegration in water at 37 °C must complete within 15 min. When the API load exceeds 20 wt%, wet granulation with a 5–10 wt% polyvinylpyrrolidone binder solution is selected because direct compression of the high-dose blend produces ejection force above 6 kN and capping defects. Finished tablets are tested for content uniformity to USP <905> and Ph. Eur. 2.9.6; in-process controls follow 21 CFR 211.110, and the nonsterile oral dosage form is released under Ph. Eur. 5.1.4. The terminal product is an uncoated or film-coated veterinary tablet packed into HDPE bottles or PVC-aluminium blisters.

Injectable Sterile Liquid Processing Requires More than Terminal Heat

Injectable solutions containing Jinge Zhili Powder Veterinary Grade API are compounded in Water for Injection cooled to 20±2 °C; the API is dissolved before pH adjustment with 0.1 M hydrochloric acid or sodium hydroxide, and tonicity is adjusted to 280–320 mOsm/kg with sodium chloride. The working active concentration is 5.0–20.0% w/v for small-volume parenterals; below 5.0% w/v, content uniformity in the filling line is controlled by continuous in-line UV or high-performance liquid chromatography at ≤ 2.0% RSD, and above 20.0% w/v the solubility margin should be verified by a forced-precipitation study in the final vehicle. The decision between terminal steam sterilisation at 121 °C for 15 min and aseptic filtration through a 0.22 μm sterilising-grade PVDF or PES cartridge is based on VICH GL3(R) forced degradation data, not on dry-powder stability alone; if thermal stability of the API is insufficient, aseptic processing is used with a pre-filtration bioburden of ≤ 10 CFU/100 mL, a filter-integrity bubble point test, and a Grade A/B environment defined by EU GMP Annex 1. Filling into USP Type I glass vials with chlorobutyl rubber stoppers is performed under nitrogen overlay when oxidation occurs; headspace oxygen is kept below 2.0% v/v for oxygen-sensitive formulations. Release testing includes bacterial endotoxins by USP <85>, particulate matter by USP <788>, sterility by USP <71>, and container closure integrity under 21 CFR 211.94. The terminal product is a clear sterile veterinary injectable solution in single-dose or multi-dose vials.

On a commercial parenteral line, the failure mode most frequently encountered is post-filtration precipitation when the final pH is maintained within 1.0 pH unit of the API’s isoelectric point or when the buffering capacity is below 10 meq/L; this is detected by in-line turbidity above 2.0 NTU after 24 h. Sterile filling is performed at 2–8 °C if the solution is not held at room temperature; hold time between sterile filtration and filling is limited to ≤ 12 h unless validation shows longer. The line uses Grade A unidirectional airflow under EU GMP Annex 1; vial washing and depyrogenation are conducted at 250 °C for 30 min for Type I glass, and rubber stoppers are autoclaved separately. If terminal sterilisation is selected, load validation includes cold-spot mapping and F₀ values of ≥ 15 min; if aseptic filtration is selected, a media fill failure rate below 0.1% is the release criterion for the line.

Hard capsule production is selected when tablet compression is not feasible due to poor API compactability or when the veterinary dose requires simple oral administration without the tooling investment of a tablet line. Jinge Zhili Powder Veterinary Grade API is filled into size 0 or size 1 hard gelatin or hypromellose capsules at 25–200 mg active per unit, corresponding to 10–40 wt% of a total fill weight of 150–400 mg; formulations below 10 mg active per capsule require a first-step 1:10 geometric pre-blend with microcrystalline cellulose to keep active concentration RSD below 5.0% before the main blend. Blending is carried out in a 200 L V-blender or bin blender at 12–15 rpm for 20–30 min, followed by encapsulation on a dosator-pin or tamping-pin machine with compaction height controlled at 5–10 mm; fill weight variation is checked every 30 min against USP <905> and Ph. Eur. 2.9.5, and dissolution is tested by USP <711> or Ph. Eur. 2.9.3. In-process controls under 21 CFR 211.110 include moisture content below 2.5% before encapsulation because higher moisture in the powder plug causes capsule shell brittleness and variable plug ejection. The terminal product is a capsule-filled oral dosage form for companion animals, packed in aluminium-aluminium or PVC-PVDC blisters to limit moisture ingress.

Granulation Binder Selection and Moisture-Dependent Particle Size

Granules for oral veterinary administration are produced with Jinge Zhili Powder Veterinary Grade API at 10–40 wt% on dry solids; the granulation route is selected according to the required bulk density and dispersibility of the final sachet or bottle product. Fluid-bed top-spray granulation with a 5–10 wt% hypromellose or povidone binder solution at inlet air 55–65 °C, product temperature 35–40 °C, and outlet relative humidity 15–20% produces porous granules with a tapped density of 0.45–0.60 g/cm³; these dissolve quickly but may be friable. High-shear granulation in a 100–300 L vertical granulator with a 5–10 wt% binder solution produces dense granules above 0.70 g/cm³ with a mean particle size of 500–1,200 μm, better flow for sachet filling, but slower wetting in the mouth. Drying is stopped at a loss on drying value of ≤ 2.5%; residual moisture above 3.0% increases granule adhesion to the drying bowl and creates microbial risk under nonsterile oral limits. The dried granulate is sieved over 0.5 mm and 2.0 mm screens; oversize material is milled through a cone mill and re-compacted. Particle size is verified by USP <786> or Ph. Eur. 2.9.12, and the final sachets are filled to a weight variation of ≤ 5.0% per Ph. Eur. 2.9.5. In-process controls under 21 CFR 211.110 require moisture and blend uniformity records; stability studies follow VICH GL3(R). The terminal product is a granulated oral dosage form packed into single-dose sachets or multi-dose HDPE containers for administration by direct oral dosing or mixing with a small amount of feed.

When the Soluble Powder Batch Fails a Water Stability Test

Water-soluble powders for mass medication of livestock are formulated by blending Jinge Zhili Powder Veterinary Grade API with a soluble carrier such as dextrose monohydrate or spray-dried lactose at an initial dry-powder strength of 5.0–50.0 wt%, then diluted at the farm into drinking water at 50–200 mg active per litre according to the veterinarian’s dose calculation and species water intake. If a finished batch fails water stability testing in hard water containing 250–300 ppm CaCO₃ at 20–25 °C, the failure is generally traced to reconstituted pH drift, oxidation, or divalent-cation complexation; reformulation with 0.1–0.3 wt% sodium metabisulphite as antioxidant and buffering of the dry blend with citric acid/sodium citrate to a reconstituted pH of 4.5–6.0 reduces precipitation and assay loss. Production is conducted in a 300–600 L ribbon mixer at 25 rpm for 60 min, followed by de-agglomeration through a 0.5 mm cone mill; ten-point sampling is required with active assay RSD ≤ 5.0%. The processing room relative humidity is held below 45% RH because the hygroscopic carrier at higher moisture uptake causes powder caking and dissolution failures; packaging must use low-moisture vapour transmission foil laminate with a desiccant pouch where necessary. If no published water solubility or water stability data are available for Jinge Zhili Powder Veterinary Grade API, the manufacturer must run a shake-flask solubility profile at 25 °C in three buffered media before finalising the formula. The terminal product is a water-soluble powder packed into foil-lined sachets, pouches, or buckets for drinking-water administration in swine, poultry, or cattle; the formulation is released under EU 2019/6 for veterinary medicinal products and, where applicable, FAMI-QS 6.0 or GMP+ BA2 for feed-related delivery.

In farm-scale water medication, water hardness and pH are not controlled to pharmacopoeial tolerances, so the finished dry powder must tolerate reconstitution in water from pH 5.0 to pH 9.0 and temperatures from 5–30 °C without precipitation for at least 24 h. Published data for this specific API configuration may be limited; solubility and stability in the final medicated water should be verified by a 24-hour in-use study according to EU 2019/6 requirements. Blending equipment is dedicated or cleaned to a carry-over limit below 10 ppm because carry-over of active powder into nonmedicated feed or water lines creates regulatory residues and cross-contamination risk.

Medicated feed premix manufacture is treated as a segregation-critical rather than dissolution-critical operation when Jinge Zhili Powder Veterinary Grade API is carried on calcium carbonate, wheat middlings, or rice husk at 10.0–20.0 wt% in the intermediate premix and diluted into final feed at 0.5–5.0 kg active per metric ton. The production sequence uses three stages of 1:10 dilution in a twin-shaft paddle mixer with a useful volume of 500–1,000 L and a mixing time of 10–15 min at a tip speed of 1.5–2.5 m/s; batch uniformity is accepted only when ten sampling points show active assay coefficient of variation ≤ 5.0% and residual carry-over after cleaning falls below the limit of quantification. Milling through a 1.0 mm screen before mixing reduces API clusters; liquid vegetable oil at 0.5–1.5 wt% is then sprayed to suppress dust and reduce segregation during bagging and transport. Pelletising after incorporation is only acceptable when moist-heat stability has been confirmed, for example at conditioning conditions of 70–80 °C for 30–45 s; if the API is heat-labile, post-pellet liquid spraying is substituted. The applicable compliance framework includes EU 2019/6, FAMI-QS 6.0, GMP+ BA2, 21 CFR 225, and ISO 22000:2018 where the mill operates a dual feed-food line. The terminal product is a medicated feed premix or pelleted feed delivered to farms, with the final inclusion rate verified by in-line mixer performance records and lot-by-lot assay.

Carry-over in premix lines is managed by sequencing batches from low active concentration to high active concentration, dedicating dust extraction sleeves, and validating equipment cleaning with swab or rinse limits below the limit of quantification. Weighing of active API at 1–10 kg per batch is conducted in a separate downflow booth with relative humidity below 45% RH; the booth air supply is filtered through HEPA H13 or higher. When the API is cohesive, a 1:1 preblend with precipitated silica at 0.1–0.5 wt% of the total formula improves flow, but silica addition must be validated because it can reduce dissolution in later gastrointestinal release testing.

Oral Solution pH Drift at 25 °C and 40 °C

Oral solutions containing Jinge Zhili Powder Veterinary Grade API are compounded at 1.0–15.0% w/v active, with a co-solvent system of propylene glycol at 5.0–20.0% w/w and purified water; the API is dissolved in the co-solvent under low-shear agitation in a 316L stainless steel vessel at 20–25 °C before the aqueous buffer is added. The pH is adjusted to ± 0.2 units of the stability optimum with 0.1 M citrate or phosphate buffer, and the solution is preserved with sodium benzoate 0.1–0.2% w/w or potassium sorbate 0.1–0.2% w/w. A 45 μm in-line filter is used before filling into amber PET or HDPE bottles with child-resistant closures; dissolved oxygen is kept below 1.0 mg/L when oxidation-susceptible APIs are handled. pH drift is monitored at 25 °C and 40 °C for 6 months; a shift greater than 0.5 pH units requires re-formulation because degradation products and solubility can move outside specification. If pH-solubility data for the API are not available, the formulation buffer cannot be selected without a pH-solubility and degradation profile study. Antimicrobial effectiveness is tested by USP <51>, and the nonsterile liquid is released under Ph. Eur. 5.1.4; container closure integrity follows 21 CFR 211.94, and stability protocols follow VICH GL3(R). The terminal product is an oral solution for direct administration or for dilution in drinking water, packaged in screw-capped bottles or unit-dose sachets.